Sireesh Appajosyula, Chief Executive Officer and Director of Hepion Pharmaceuticals, Inc., filed a Form 4 on October 27, 2026, reporting the acquisition of stock options on October 23, 2026.

Key Highlights

  • Reporting person: Sireesh Appajosyula, serving as Chief Executive Officer and Director of Hepion Pharmaceuticals, Inc.
  • Options acquired: 1,530,000 stock options granted on October 23, 2026, at an exercise price of $0.14 per share.
  • Expiration date: The options expire on October 23, 2036.
  • Vesting schedule: 127,500 options vest in equal amounts monthly over 12 months from the date of grant, according to the filing's footnote.
  • Price of derivative security: $0, as reported in the filing.
  • Beneficial ownership after transaction: 2,875,500 derivative securities beneficially owned following the reported transaction.

Stock Option Grant Details for Hepion Pharmaceuticals CEO Appajosyula

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Sireesh Appajosyula, who holds the roles of Chief Executive Officer and Director at Hepion Pharmaceuticals, Inc. (OTC:HEPA), acquired 1,530,000 stock options on October 23, 2026. The transaction code reported is "A," indicating an acquisition. The options carry an exercise price of $0.14 and are linked to the underlying security of common stock, with 1,530,000 shares of common stock underlying the derivative.

The filing discloses that the price of the derivative security at acquisition was $0. The options are exercisable beginning October 23, 2026, and will expire on October 23, 2036. As noted in the explanation of responses, "127,500 options vest in equal amounts monthly over 12 months from date of grant." Following this transaction, the filing reports that Appajosyula beneficially owns 2,875,500 derivative securities on a direct basis. No non-derivative securities transactions were reported in Table I of this filing.

The Form 4 was filed by one reporting person and signed by Sireesh Appajosyula on October 27, 2026. The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan, as that checkbox was not selected on the form.

What Was Disclosed

Hepion Pharmaceuticals CEO Sireesh Appajosyula reported the acquisition of 1,530,000 stock options at an exercise price of $0.14, granted October 23, 2026, expiring October 23, 2036, with 127,500 options vesting monthly over 12 months. Post-transaction beneficial ownership stands at 2,875,500 derivative securities.